224 related articles for article (PubMed ID: 16489070)
1. Expression of enhancer of zeste homologue 2 is significantly associated with increased tumor cell proliferation and is a marker of aggressive breast cancer.
Collett K; Eide GE; Arnes J; Stefansson IM; Eide J; Braaten A; Aas T; Otte AP; Akslen LA
Clin Cancer Res; 2006 Feb; 12(4):1168-74. PubMed ID: 16489070
[TBL] [Abstract][Full Text] [Related]
2. EZH2 expression is associated with high proliferation rate and aggressive tumor subgroups in cutaneous melanoma and cancers of the endometrium, prostate, and breast.
Bachmann IM; Halvorsen OJ; Collett K; Stefansson IM; Straume O; Haukaas SA; Salvesen HB; Otte AP; Akslen LA
J Clin Oncol; 2006 Jan; 24(2):268-73. PubMed ID: 16330673
[TBL] [Abstract][Full Text] [Related]
3. Enhancer of zeste homologue 2 expression in breast carcinoma smears in relationship with p53, Ki-67 and other prognostic parameters.
Athanassiadou AM; Tsipis A; Patsouris E; Gonidi M; Nicolopoulou-Stamati P; Chelidonis G; Athanassiadou P
Acta Cytol; 2011; 55(2):180-6. PubMed ID: 21325804
[TBL] [Abstract][Full Text] [Related]
4. Enhancer of zeste homolog 2 expression is associated with tumor cell proliferation and metastasis in gastric cancer.
Choi JH; Song YS; Yoon JS; Song KW; Lee YY
APMIS; 2010 Mar; 118(3):196-202. PubMed ID: 20132185
[TBL] [Abstract][Full Text] [Related]
5. Identification of EZH2 as a molecular marker for a precancerous state in morphologically normal breast tissues.
Ding L; Erdmann C; Chinnaiyan AM; Merajver SD; Kleer CG
Cancer Res; 2006 Apr; 66(8):4095-9. PubMed ID: 16618729
[TBL] [Abstract][Full Text] [Related]
6. Increased risk for distant metastasis in patients with familial early-stage breast cancer and high EZH2 expression.
Alford SH; Toy K; Merajver SD; Kleer CG
Breast Cancer Res Treat; 2012 Apr; 132(2):429-37. PubMed ID: 21614565
[TBL] [Abstract][Full Text] [Related]
7. Downregulation of EZH2 decreases growth of estrogen receptor-negative invasive breast carcinoma and requires BRCA1.
Gonzalez ME; Li X; Toy K; DuPrie M; Ventura AC; Banerjee M; Ljungman M; Merajver SD; Kleer CG
Oncogene; 2009 Feb; 28(6):843-53. PubMed ID: 19079346
[TBL] [Abstract][Full Text] [Related]
8. EZH2 overexpression in different immunophenotypes of breast carcinoma and association with clinicopathologic features.
Guo S; Li X; Rohr J; Wang Y; Ma S; Chen P; Wang Z
Diagn Pathol; 2016 Apr; 11():41. PubMed ID: 27113214
[TBL] [Abstract][Full Text] [Related]
9. Prognostic impact of the cancer stem cell related markers ALDH1 and EZH2 in triple negative and basal-like breast cancers.
De Brot M; Rocha RM; Soares FA; Gobbi H
Pathology; 2012 Jun; 44(4):303-12. PubMed ID: 22544210
[TBL] [Abstract][Full Text] [Related]
10. Polycomb group protein EZH2 is frequently expressed in inflammatory breast cancer and is predictive of worse clinical outcome.
Gong Y; Huo L; Liu P; Sneige N; Sun X; Ueno NT; Lucci A; Buchholz TA; Valero V; Cristofanilli M
Cancer; 2011 Dec; 117(24):5476-84. PubMed ID: 21713757
[TBL] [Abstract][Full Text] [Related]
11. The value of TOP2A, EZH2 and paxillin expression as markers of aggressive breast cancer: relationship with other prognostic factors.
Panousis D; Patsouris E; Lagoudianakis E; Pappas A; Kyriakidou V; Voulgaris Z; Xepapadakis G; Manouras A; Athanassiadou AM; Athanassiadou P
Eur J Gynaecol Oncol; 2011; 32(2):156-9. PubMed ID: 21614903
[TBL] [Abstract][Full Text] [Related]
12. Immunohistochemical analysis of pRb2/p130, VEGF, EZH2, p53, p16(INK4A), p27(KIP1), p21(WAF1), Ki-67 expression patterns in gastric cancer.
Mattioli E; Vogiatzi P; Sun A; Abbadessa G; Angeloni G; D'Ugo D; Trani D; Gaughan JP; Vecchio FM; Cevenini G; Persiani R; Giordano A; Claudio PP
J Cell Physiol; 2007 Jan; 210(1):183-91. PubMed ID: 16998811
[TBL] [Abstract][Full Text] [Related]
13. Clinical and biological relevance of enhancer of zeste homolog 2 in triple-negative breast cancer.
Hussein YR; Sood AK; Bandyopadhyay S; Albashiti B; Semaan A; Nahleh Z; Roh J; Han HD; Lopez-Berestein G; Ali-Fehmi R
Hum Pathol; 2012 Oct; 43(10):1638-44. PubMed ID: 22436627
[TBL] [Abstract][Full Text] [Related]
14. High expression of EZH2 is associated with tumor proliferation and prognosis in human oral squamous cell carcinomas.
Kidani K; Osaki M; Tamura T; Yamaga K; Shomori K; Ryoke K; Ito H
Oral Oncol; 2009 Jan; 45(1):39-46. PubMed ID: 18619895
[TBL] [Abstract][Full Text] [Related]
15. Aberrant expression of enhancer of zeste homologue 2, correlated with HIF-1α, refines relapse risk and predicts poor outcome for breast cancer.
Dong M; Fan XJ; Chen ZH; Wang TT; Li X; Chen J; Lin Q; Wen JY; Ma XK; Wei L; Ruan DY; Lin ZX; Liu Q; Wu XY; Wan XB
Oncol Rep; 2014 Sep; 32(3):1101-7. PubMed ID: 25017254
[TBL] [Abstract][Full Text] [Related]
16. Enhancer of zeste homolog 2 expression is associated with tumor cell proliferation and invasion in cervical cancer.
Fang J; Zhang M; Li Q
Am J Med Sci; 2011 Sep; 342(3):198-204. PubMed ID: 21629038
[TBL] [Abstract][Full Text] [Related]
17. Dietary omega-3 polyunsaturated fatty acids suppress expression of EZH2 in breast cancer cells.
Dimri M; Bommi PV; Sahasrabuddhe AA; Khandekar JD; Dimri GP
Carcinogenesis; 2010 Mar; 31(3):489-95. PubMed ID: 19969553
[TBL] [Abstract][Full Text] [Related]
18. Expression profile of the polycomb group protein enhancer of Zeste homologue 2 and its prognostic relevance in renal cell carcinoma.
Hinz S; Weikert S; Magheli A; Hoffmann M; Engers R; Miller K; Kempkensteffen C
J Urol; 2009 Dec; 182(6):2920-5. PubMed ID: 19846140
[TBL] [Abstract][Full Text] [Related]
19. Aberrant expression of EZH2 is associated with pathological findings and P53 alteration.
Shiogama S; Yoshiba S; Soga D; Motohashi H; Shintani S
Anticancer Res; 2013 Oct; 33(10):4309-17. PubMed ID: 24122997
[TBL] [Abstract][Full Text] [Related]
20. Invasive breast carcinomas in Ghana: high frequency of high grade, basal-like histology and high EZH2 expression.
Pang J; Toy KA; Griffith KA; Awuah B; Quayson S; Newman LA; Kleer CG
Breast Cancer Res Treat; 2012 Aug; 135(1):59-66. PubMed ID: 22527102
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]